Last reviewed · How we verify
CART-meso
At a glance
| Generic name | CART-meso |
|---|---|
| Sponsor | University of Pennsylvania |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CART-meso in Mesothelin Expressing Cancers (PHASE1)
- CART-meso Long-term Follow-up
- The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer (EARLY_PHASE1)
- Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer (NA)
- Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer (PHASE1)
- Autologous Redirected RNA Meso-CIR T Cells (PHASE1)
- A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma (PHASE1)
- Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CART-meso CI brief — competitive landscape report
- CART-meso updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI